Health Care [ 6/12 ] | Biotechnology [ 40/75 ]
NASDAQ | Common Stock
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries.
The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and NanobiotixS. A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy.
The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 25, 24 | 3.55 Increased by +2.19 K% | -0.19 Increased by +1.97 K% |
| Nov 14, 23 | -0.22 Decreased by -9.67% | -0.33 Increased by +33.33% |
| Aug 15, 23 | -0.20 Increased by +48.82% | -0.28 Increased by +28.57% |
| May 12, 23 | -0.22 Increased by +14.99% | -0.27 Increased by +18.52% |
| Mar 27, 23 | -0.17 Decreased by -40.26% | -0.27 Increased by +37.04% |
| Nov 11, 22 | -0.20 | - |
| Aug 12, 22 | -0.39 | - |
| May 12, 22 | -0.26 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | N/A Decreased by N/A% | 383.73 M Increased by +2.20 K% | - - |
| Sep 30, 23 | 0.00 Decreased by N/A% | -24.04 M Decreased by -9.79% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 - | -21.39 M - | Decreased by N/A% - |
| Mar 31, 23 | 0.00 - | -24.00 M - | Decreased by N/A% - |
| Dec 31, 22 | 0.00 - | -18.28 M - | Decreased by N/A% - |
| Sep 30, 22 | 0.00 - | -21.90 M - | Decreased by N/A% - |